Main menu

Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market


Nanopore sequencing offers a transformational new approach for robust and accurate genetic characterisation of biological materials, enabling the release of novel therapeutics with more certainty and safety assurance than ever before.


Oxford Nanopore Technologies plc (Oxford Nanopore) and PathoQuest today announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis (ISA) test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.

Oxford Nanopore’s technology can, with very high accuracy, read any length of native DNA, enabling the identification and comprehensive sequence assessment of genomic insertion sites without the risk of missing off target integrations that may negatively impact the therapeutic or the patient. Additionally, PathoQuest’s ISA test is positioned to provide significant benefits (speed, accuracy, confidence in the results) compared to traditional sequencing methods.

We are entering the era of personalised medicine and with that, the way in which we develop, manufacture and provide quality control over advanced therapeutics is progressing. Methods that can offer complete characterisation more quickly will ultimately enhance and further improve the drug development pathway. Oxford Nanopore’s rapid, information-rich sequencing is a natural fit for this challenge.

Oxford Nanopore and PathoQuest intend the ISA test to be the first in a line of sequencing-based quality control test solutions targeting the biopharma genetic characterisation and safety markets.

Gordon Sanghera, CEO, Oxford Nanopore Technologies, commented:

“We are excited to be working with PathoQuest to develop and offer the first Good Manufacturing Practice (GMP) accredited Integration Site Analysis test with nanopore sequencing. We believe this will have a significant future impact by improving test accuracy and turnaround times for genetic characterisation for multiple applications in biopharma.”

Jean-François Brepson, CEO, PathoQuest commented:

“As innovator companies continue to bring exciting new therapies to market, there is a critical need for innovative biosafety and characterisation strategies.” Mr. Brepson continued, “this new Integration Site Analysis method, powered by Oxford Nanopore sequencing, will enable our customers to progress their biologics programmes with more certainty than ever before.”

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag